Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical Features and Long-term Prognosis of Crohn's Disease in Korea: Results from the Prospective CONNECT Study.

Gut and liver·2022

Same author

ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma.

Cell death & disease·2022

Same author

Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics.

Diagnostics (Basel, Switzerland)·2022

Same author

Prognostic value of complete metabolic response on ¹⁸F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer.

Journal of gynecologic oncology·2022

Same author

Disruption of YCP4 enhances freeze-thaw tolerance in Saccharomyces cerevisiae.

Biotechnology letters·2022

Same author

Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer.

Diagnostics (Basel, Switzerland)·2022

Search research articles

Related Experiment Video

Updated: Jul 22, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Identifying High Recurrence Risk in Breast Carcinoma Patients Through Spatial Transcriptomic Analysis.

Jinah Chu¹, Sung-Im DO², Hyun-Soo Kim³

¹Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Anticancer Research

|September 30, 2024

Summary

High Oncotype DX Recurrence Score (ORS) breast cancer shows distinct stromal gene expression, including immune response and interferon pathways. This spatial transcriptomic analysis reveals key differences in high-risk tumors.

Keywords:

Breast Oncotype DX Recurrence Score invasive carcinoma spatial transcriptomics tumor recurrence

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Spatial Profiling of Protein and RNA Expression in Tissue: An Approach to Fine-Tune Virtual Microdissection

Spatial Profiling of Protein and RNA Expression in Tissue: An Approach to Fine-Tune Virtual Microdissection

Published on: July 6, 2022

Related Experiment Videos

Last Updated: Jul 22, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Spatial Profiling of Protein and RNA Expression in Tissue: An Approach to Fine-Tune Virtual Microdissection

Spatial Profiling of Protein and RNA Expression in Tissue: An Approach to Fine-Tune Virtual Microdissection

Published on: July 6, 2022

Area of Science:

Genomics and Molecular Biology
Oncology
Bioinformatics

Background:

Spatially resolved transcriptomic analysis for breast carcinoma recurrence risk remains underexplored.
Identifying genetic features associated with high Oncotype DX Recurrence Score (ORS) is crucial for personalized treatment.

Purpose of the Study:

To identify distinct genetic features of breast carcinoma associated with a high Oncotype DX Recurrence Score (ORS) using spatial transcriptomics.
To compare gene expression profiles between high-risk (ORS-H) and non-high-risk (ORS-NH) breast cancer groups.

Main Methods:

Digital spatial profiling and bioinformatic analyses were employed.
Patients were stratified into ORS-high (ORS-H) and ORS-non-high (ORS-NH) groups.
Spatial transcriptomic profiles were investigated to identify differentially expressed genes and pathways.

Main Results:

Lysozyme (LYZ), complement C1q C chain (C1QC), and complement C1q B chain (C1QB) showed the highest fold changes in the stromal compartment of the ORS-H group.
Gene ontology analysis revealed significant up-regulation of immune response genes (lymphocyte-mediated, adaptive, and leukocyte-mediated immunity) in the ORS-H stroma.
Gene set enrichment analysis identified significant positive enrichment of interferon (IFN) response and complement pathways in the ORS-H stromal compartment.

Conclusions:

Significant differences in gene expression and spatial transcriptional activity exist between ORS-H and ORS-NH breast carcinomas.
The stromal compartment of ORS-H tumors exhibits significant up-regulation of cell-mediated immunity, IFN response, and complement C1q-related genes.
Further validation in larger cohorts is warranted to confirm these findings for high-risk breast cancer stratification.